For following the competition: what moved in each program, several studies read as one move.
- orelabrutinib
- remibrutinib
- ocrelizumab
- + 12 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Multiple Sclerosis, Chronic Progressive to watchlistEvery Monday by email · turn it off any timePro · free during the beta